ResearcherNara Medical UniversityNo recent work listed
Chiho Ohbayashi
Matched on ORCID iD 0000-0002-8046-9508; OpenAlex author ID A5053890395. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2015: 3 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper
Papers 7
- Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
- Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗
- K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of p… Last author DOI 10.1371/journal.pone.0193692↗
- Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
- Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Co-author DOI 10.1002/jhbp.258↗
- Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Co-author DOI 10.1007/s00268-015-3205-3↗
- Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1304-0↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masayuki Sho · 7 shared papers, 2015–2019 · strength 0.43
- Paper Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. DOI 10.1016/j.pan.2019.05.461↗
- Paper Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenoc… DOI 10.1007/s00423-018-1709-7↗
- Paper K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspir… DOI 10.1371/journal.pone.0193692↗
- Kimihiko Kichikawa · 6 shared papers, 2015–2019 · strength 0.36
- Paper Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. DOI 10.1016/j.pan.2019.05.461↗
- Paper Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenoc… DOI 10.1007/s00423-018-1709-7↗
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Takahiro Akahori · 6 shared papers, 2015–2019 · strength 0.36
- Paper Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. DOI 10.1016/j.pan.2019.05.461↗
- Paper Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenoc… DOI 10.1007/s00423-018-1709-7↗
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Minako Nagai · 6 shared papers, 2015–2019 · strength 0.36
- Paper Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. DOI 10.1016/j.pan.2019.05.461↗
- Paper Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenoc… DOI 10.1007/s00423-018-1709-7↗
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Toshihiro Tanaka · 5 shared papers, 2015–2019 · strength 0.31
- Paper Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. DOI 10.1016/j.pan.2019.05.461↗
- Paper Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenoc… DOI 10.1007/s00423-018-1709-7↗
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Satoshi Nishiwada · 4 shared papers, 2015–2018 · strength 0.22
- Paper Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenoc… DOI 10.1007/s00423-018-1709-7↗
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Paper Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. DOI 10.1007/s00268-015-3205-3↗
- Yoshiyuki Nakajima · 4 shared papers, 2015–2016 · strength 0.20
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Paper Importance of resectability status in neoadjuvant treatment for pancreatic cancer. DOI 10.1002/jhbp.258↗
- Paper Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. DOI 10.1007/s00268-015-3205-3↗
- Shoichi Kinoshita · 4 shared papers, 2015–2016 · strength 0.20
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Paper Importance of resectability status in neoadjuvant treatment for pancreatic cancer. DOI 10.1002/jhbp.258↗
- Paper Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. DOI 10.1007/s00268-015-3205-3↗
- Hideyuki Nishiofuku · 3 shared papers, 2015–2019 · strength 0.19
- Paper Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. DOI 10.1016/j.pan.2019.05.461↗
- Paper Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. DOI 10.1016/j.amjsurg.2015.10.034↗
- Paper Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. DOI 10.1007/s00423-015-1304-0↗
- Kota Nakamura · 2 shared papers, 2018–2019 · strength 0.16
- Kenji Nakagawa · 2 shared papers, 2018–2019 · strength 0.16
- Naoya Ikeda · 2 shared papers, 2018–2019 · strength 0.16
- Tadataka Takagi · 1 shared paper, 2019 · strength 0.09
- Yoko Sekita‐Hatakeyama · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.